Sandra Demaria
Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.
Overview
Sandra Demaria is Vice President of the Society for Immunotherapy of Cancer for 2025-2026 and a professor at Weill Cornell Medicine. Her laboratory studies how radiotherapy modulates anti-tumour immunity and how it can be combined with immune checkpoint blockade, with a strong focus on breast cancer. She is a widely cited contributor to the field of radiation-induced in situ vaccination.
Pages like this
not linked directly; found by shared links- PersonDorraya El-Ashry
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonSunil Lakhani
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonPriya Rastogi
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonIsabel T. Rubio
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonSuzette Delaloge
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonRita Schmutzler
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonDerrick S. Haslem
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist.
- PersonAntonio Rosato
Shares the tags leadership, clinician-scientist, immunotherapy.